Prof. Dr. Andreas Mackensen

Lehrstuhl für Innere Medizin V

Efficient Elimination of Cells from Patients with Different AML Subtypes by Dual-Targeting Triplebody 33-16-123 (2019) Braciak T, Fenn N, Wildenhain S, Schiller C, Roskopf C, Schubert I, Jacob U, et al. Conference contribution Design and Implementation of a Single Source Multipurpose Hospital-Wide Clinical Trial Registry. (2019) Sommer M, Kirchner M, Gulden C, Egloffstein S, Lux MP, Beckmann M, Mackensen A, Prokosch HU Journal article Design and Implementation of a Single Source Multipurpose Hospital-Wide Clinical Trial Registry (2019) Sommer M, Kirchner M, Gulden C, Egloffstein S, Lux MP, Beckmann M, Mackensen A, Prokosch HU Conference contribution A human CD22 transgenic, myc-driven lymphoma model to test effects of targeted therapies on lymphoma immune microenvironment in immunecompetent mice (2019) Wagner F, Brandl C, Petkovic S, Emmerich C, Nitschke L, Mackensen A, Müller F Conference contribution 2-Deoxyglucose induced unfolded protein response enhances efficacy of immunotoxin Moxetumomab pasudotox against lymphoma and leukemia xenografts (2019) Wagner F, Meier C, Krumbholz M, Metzler M, Mackensen A, Müller F Conference contribution Bone marrow stroma cells promote a S100A8/A9high subset of chemoresistant AML blasts with distinct metabolic features in a Jak/STAT-dependent manner (2019) Böttcher M, Panagiotidis K, Mentz K, Bruns H, Mackensen A, Mougiakakos D, Völkl S Conference contribution Development of pseudomonas exotoxin based Duotoxins for the treatment of hematologic malignancies (2019) Ammon AM, Emmerich C, Mellenthin L, Mackensen A, Müller F Conference contribution Daratumomab for the treatment of relapsed multiple myeloma involving the central nervous system: a case report (2019) Brandt A, Seuß H, Mackensen A, Rösler W Conference contribution Monitoring of the immunometabolic profile of reconstituting leukocytes upon autologous peripheral blood stem cell transplantation (2019) Richter S, Jacobs B, Böttcher M, Stoll A, Böttcher-Loschinski R, Mackensen A, Mougiakakos D Conference contribution Successful targeting of BRAF V600E mutation with vemurafenib in a treatment-resistant extragonadal non-seminomatous germ cell tumor (2019) Meintker L, Haller F, Tögel L, Schmidt D, Waibel H, Mackensen A, Meidenbauer N Conference contribution